Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies.

Am J Clin Dermatol

Department of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA.

Published: September 2023

AI Article Synopsis

  • Protein kinase inhibitors and immunotherapy have significantly improved treatment outcomes for advanced melanoma, but they also introduce various drug-related toxicities.
  • This review highlights dermatologic adverse events associated with targeted therapies (like BRAF and MEK inhibitors) and immunotherapy, including talimogene laherparepvec.
  • Recognizing and managing these skin-related toxicities is crucial since they can affect patients' quality of life and are linked to treatment response and survival rates.

Article Abstract

The advent of protein kinase inhibitors and immunotherapy has profoundly improved the management of advanced melanoma. However, with these therapeutic advancements also come drug-related toxicities that have the potential to affect various organ systems. We review dermatologic adverse events from targeted (including BRAF and MEK inhibitor-related) and less commonly used melanoma treatments, with a focus on diagnosis and management. As immunotherapy-related toxicities have been extensively reviewed, herein, we discuss injectable talimogene laherparepvec and touch on recent breakthroughs in the immunotherapy space. Dermatologic adverse events may severely impact quality of life and are associated with response and survival. It is therefore essential that clinicians are aware of their diverse presentations and management strategies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10796164PMC
http://dx.doi.org/10.1007/s40257-023-00790-8DOI Listing

Publication Analysis

Top Keywords

dermatologic adverse
12
adverse events
12
diagnosis management
8
management dermatologic
4
events systemic
4
systemic melanoma
4
melanoma therapies
4
therapies advent
4
advent protein
4
protein kinase
4

Similar Publications

Background: Postoperative nausea and vomiting (PONV) are common complications following general anesthesia, particularly in gynecological laparoscopic surgeries. This study aims to evaluate the effect of intraoperative noise isolation on PONV incidence.

Method: This single-center, prospective, randomized controlled trial will enroll 192 adult patients undergoing laparoscopic gynecological surgery.

View Article and Find Full Text PDF

Objectives: DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) trials.

Methods: Eligible patients completing the 24-week DARWIN 1 (filgotinib plus methotrexate) and DARWIN 2 (filgotinib monotherapy) trials could enrol.

View Article and Find Full Text PDF

Conservative Approach to Treatment of Cyclosporine-Induced Gingival Hyperplasia With Azithromycin and Chlorhexidine.

Cutis

December 2024

Dr. Krevh is from the College of Medicine, Northeast Ohio Medical University, Rootstown. Dr. Korman is from the Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus.

Treatment of symptomatic cyclosporine-induced gingival hyperplasia can be challenging, especially if continued use of cyclosporine is necessary for adequate control of the underlying disease. We outline a simplified approach for conservatively managing cyclosporine-induced gingival hyperplasia using azithromycin and chlorhexidine.

View Article and Find Full Text PDF

Acne vulgaris (AV) is a common chronic inflammatory skin disorder that commonly lasts from adolescence to adulthood and has serious social and psychological consequences. Current treatments typically use antibacterial drugs, which contributes to the rise in antibacterial drug resistance. Spironolactone, a potassium-sparing diuretic with anti-androgen effects, has been used off-label to treat acne by lowering sebum production.

View Article and Find Full Text PDF

Background: Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), often results in significant morbidity among patients with moderate to severe forms. While biologics and small molecules are effective in inducing remission, many patients experience refractory disease or extraintestinal manifestations. This study assesses the safety and efficacy of dual-targeted therapy in IBD patients treated at the Inflammatory Bowel Disease Center.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!